Influence Of GGCX Rs11676382、rs12714145 And Rs67988001 Genetic Polymorphisms On Warfarin Dose

[Objective] To investigate the influence of the GGCX rs11676382、rs12714145 and rs67988001 genetic polymorphisms on warfarin dose in patients with heart valve replacement.[Methods] Collected 100 patients who were operated with heart valve replacement in the Department of Cardiovascular Surgery of Fujian Provincial Hospital from November 2013 to August 2014. Using the method of Polymerase Chain Reaction(PCR)、gene sequencing to detected these cases after valve surgery patients of long-term oral warfarin GGCX rs11676382、rs12714145 and rs67988001 genetic polymorphism, grouped according to genotype, compare the average dose of warfarin of different genotypes.[Results] We have not found GGCX rs11676382 G mutations. The frequencies of rs12714145 CC, TC, TT were 36 cases, 50 cases, 14 cases, the average daily dose of warfarin were 3.26 mg,3.07 mg,3.28 mg, the difference was not statistically significant(P= 0.334). The frequencies of rs67988001 CC, TC, TT were 44 cases, 46 cases, 10 cases, the average daily warfarin dose were 3.18 mg,3.17 mg,3.13 mg, the difference was not statistically significant(P =0.843).[Conclusion] GGCX rs12714145 and rs67988001 genetic polymorphisms were not associated with the difference of individual warfarin dose. GGCX rs11676382 genetic polymorphism associated with the difference of individual warfarin dose is unknown.